JNJ-90009530: A phase 1 trial of JNJ-90009530 in people with relapsed or refractory B cell non-Hodgkin lymphoma
This trial is testing the treatment JNJ-90009530 in adults with B-cell non-Hodgkin lymphoma (NHL) which has returned after (relapsed) or not responded to (refractory) treatment.
You can share the following isrctn.com Identifier with your medical team so they can find out more about the trial: ISRCTN17666983
Trial aim and background
The aim of this trial is to find out whether the medication JNJ-90009530 can be used in future trials for the treatment of B-cell NHLwhich has relapsed, or is refractory after two lines of treatment. It aims to see what side effects it may have, how long it stays in the body and how the body responds to it.
JNJ-90009530 is a form of CAR-T therapy where the patient's own T cells are used to treat the cancer.
This is a phase 1 (early phase) trial. Little is known about the safety and effectiveness of this treatment. You might not benefit from the treatment, but the trial will give important information about this new treatment, which could help other people in the future.
Who can enter
Adults with B-cell NHL who have relapsed or refractory disease after at least two treatments may be eligible for this trial.
Locations
Recruitment is taking place at University College London Hospitals NHS Foundation Trust, London.
Further information
More information about what treatments are involved, the criteria you must meet in order to take part in the trial and where this trial is taking place are available at: https://www.isrctn.com/ISRCTN17666983
Lymphoma Action are not able to refer people to specific trials. If you are interested in taking part in this trial we recommend that you print the trial summary and discuss it with your medical team. They can advise you on whether you might be eligible for the trial and how you can take part based on your individual circumstances.